Similar articles for PMID: 22239291

Year	Number of Results
1987	1
1988	1
1989	1
1990	1
1991	1
1992	2
1995	1
1996	3
1997	3
2000	8
2001	3
2002	3
2003	12
2004	10
2005	12
2006	13
2007	28
2008	19
2009	19
2010	11
2011	23
2012	30
2013	45
2014	44
2015	27
2016	19
2017	17
2018	14
2019	14
2020	14
2021	8
2022	10
2023	9
2024	1

1

Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.

Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J. Lee P, et al. J Am Geriatr Soc. 2012 Jan;60(1):51-9. doi: 10.1111/j.1532-5415.2011.03773.x. J Am Geriatr Soc. 2012. PMID: 22239291 Free article. Clinical Trial.

2

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.

Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Mullins P, et al. Clin Ther. 2007 Aug;29(8):1607-19. doi: 10.1016/j.clinthera.2007.08.020. Clin Ther. 2007. PMID: 17919543

3

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.

Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Fritsche A, et al. Ann Intern Med. 2003 Jun 17;138(12):952-9. doi: 10.7326/0003-4819-138-12-200306170-00006. Ann Intern Med. 2003. PMID: 12809451 Clinical Trial.

4

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. Semlitsch T, et al. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4. Cochrane Database Syst Rev. 2020. PMID: 33166419 Free PMC article.

5

Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.

Fulcher GR, Gilbert RE, Yue DK. Fulcher GR, et al. Intern Med J. 2005 Sep;35(9):536-42. doi: 10.1111/j.1445-5994.2005.00902.x. Intern Med J. 2005. PMID: 16105155 Clinical Trial.

6

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC. Home PD, et al. Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12. Diabetes Obes Metab. 2015. PMID: 24957785 Free PMC article. Clinical Trial.

7

Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.

Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M. Rosenstock J, et al. J Diabetes Complications. 2014 Sep-Oct;28(5):742-9. doi: 10.1016/j.jdiacomp.2014.04.003. Epub 2014 Apr 16. J Diabetes Complications. 2014. PMID: 24856612 Free PMC article. Clinical Trial.

8

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.

Owens DR, Traylor L, Mullins P, Landgraf W. Owens DR, et al. Diabetes Res Clin Pract. 2017 Feb;124:57-65. doi: 10.1016/j.diabres.2016.10.022. Epub 2016 Nov 9. Diabetes Res Clin Pract. 2017. PMID: 28092788

9

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group. Yki-Järvinen H, et al. Diabetes Care. 2000 Aug;23(8):1130-6. doi: 10.2337/diacare.23.8.1130. Diabetes Care. 2000. PMID: 10937510 Clinical Trial.

10

Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.

Porcellati F, Lin J, Lucidi P, Bolli GB, Fanelli CG. Porcellati F, et al. Medicine (Baltimore). 2017 Feb;96(5):e6022. doi: 10.1097/MD.0000000000006022. Medicine (Baltimore). 2017. PMID: 28151905 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

378 results

Results by year